Mr Willesee was appointed to the Board on 16 September 2011. Mr Willesee is an experienced director in the small capitalisation sector of the ASX. Mr Willesee brings a broad range of experience in company administration, corporate governance, company public listings, merger and acquisition transactions, reconstructions and corporate finance from his background with listed and unlisted public and other companies.

Mr Willesee has a Master of Commerce, Post-Graduate Diploma in Business (Economics and Finance), a Graduate Diploma of Applied Corporate Governance, a Diploma in Education and a Bachelor of Business. He is also a Fellow of the Financial Services Institute of Australia, a member of CPA Australia and a Chartered Secretary. 

Mr Willesee resides in Perth.

Mr Pellegrino was appointed Executive Managing Director on 1 November 2009, having served as a Non-Executive Director since 1 September 2008.

Mr Pellegrino has operated in public practice for more than 15 years as an accountant and financial adviser, in addition to previously serving as an international marketing executive for a listed biotechnology company. He is the founder and Director of the Stanford Group of Companies.

Mr Pellegrino was appointed Executive Managing Director of BioProspect in 2009, with the aim of maximising the Company's investment in Re Gen Wellness Products Pty Ltd. Mr Pellegrino's experience in international marketing, particularly within the Asian region, will be essential in securing long-term growth for the business.

He holds a Bachelor of Arts and a Bachelor of Business in Accounting.

Mr Khouri was appointed to the Board on 16 September 2011. He has a broad range of corporate experience, having served as a director of Gun Capital Corporate and Gun Capital Management and been involved with a number of ASX-listed companies, including Cape Lambert Iron Limited.

Jacob also founded and operates a successful mechanical engineering business, and has a solid understanding of new market trends and sustainability issues.

 

Executive Management

Mr May was appointed COO on 27 November 2009.

Mr May's career has included senior roles within the Orica Group of companies, where he successfully managed multi-million dollar product and technology portfolios for Australian and overseas markets.

In 2001, Mr May established Xavca Pty Ltd, a business development consultancy company with clients including Syngenta (Switzerland), Sorex International (UK), Babolna Bioenvironmental (Hungary) and AgNova Technologies (Australia).

Mr May is an Associate Fellow of the Australian Institute of Management and a graduate member of the Australian Institute of Company Directors. Mr May is an active member of the Australian Environmental Pest Managers Association (AEPMA) and has established excellent contacts within the global pest management industry in addition to the general agribusiness and animal health sectors.

His educational qualifications include a Bachelor of Applied Science degree with first class honours from Queensland University and an MBA (majoring in international marketing) from the Queensland University of Technology.

Mr Johnston is a CPA and holds a Diploma in Business Studies for Accountancy and is a graduate member of the Australian Institute of Company Directors. He has 39 years' experience in finance and management.  

Mr Johnston commenced his career with Orica Pty Ltd (formerly ICI Australia Pty Ltd) in 1971 and went on to serve in senior roles including Chief Financial Officer of ICI/Dulux PNG Pty Ltd, Pension Fund Accountant, Engineering Project Accountant and Chief Financial Officer of CropCare Australasia Pty Ltd. In 2000, he left Orica to become Chief Financial Officer and Company Secretary of Griffin Corporation Pty Ltd, a 49% subsidiary of DuPont.

Mr Johnston is responsible for BioProspect's capital management, fund raising needs and compliance with the Companies Act and ASX Listing Rules, as well as internal and external reporting requirements.

An integral part of BioProspect's core business is its ability to combine scientific expertise with commercial awareness, thereby aiding the development of innovative technologies and products. The Company maintains R&D collaborations with a number of Australian and international research institutions, including:

• The University of Western Sydney
• Southern Cross University (Centre for Phytochemistry & Pharmacology)
• University of Adelaide
• University of New England